OCD
Conditions
Brief summary
To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma concentration and the transporter occupancy from OCD patients treated with escitalopram. To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the PK-PD modeling in OCD patients treated with escitalopram.
Detailed description
To measure plasma concentration of escitalopram in OCD patients treated with escitalopram. To measure serotonin transporter occupancy by escitalopram in OCD patients treated with escitalopram. To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram.
Interventions
None listed
Sponsors
Seoul National University Hospital
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of OCD based on Diagnostic and Statistical Manual(DSM)-IV criteria * no change of escitalopram dosage in 6 weeks
Exclusion criteria
* psychiatric comorbidity other than OCD * History of head injury, epilepsy, other general medical disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serotonin transporter occupancy | 72hr after oral administration of escitalopram |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| genotype | baseline | — |
| Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score | baseline | scale for the severity of Obsessive-compulsive symptoms |
| serotonin transporter occupancy | within the first 24hrs after oral administration of escitalopram | serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram |
| escitalopram plasma concentration | within 72 hours after oral administration of escitalopram | plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram |
Countries
South Korea
Outcome results
None listed